At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease
In Brief
A Phase 3 clinical trial evaluating prednisone, methylprednisolone, and 1 other intervention for Graft Versus Host Disease and Recurrent Adult Acute Lymphoblastic Leukemia. Completed, enrolled 164 participants across 1 site.
Detailed Summary
This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease (GVHD). Glucocorticoids, such as prednisone or methylprednisolone at a starting dose of 2 mg/kg/day are standard treatment for acute graft-versus-host disease caused by a donor stem cell transplant. It is not yet known whether low-dose glucocorticoids are more effective than standard-dose glucocorticoids in treating acute graft-versus-host-disease
Study Details
Timeline
Interventions
immunosuppressive drug
immunosuppressive drug
Ancillary studies